J&J companies ally with Orexo for asthma, COPD programmes
This article was originally published in Scrip
Executive Summary
In a further demonstration of Johnson & Johnson's commitment to new treatment approaches for respiratory disease, two companies in the J&J family have reached an alliance and licensing deal with Orexo that taps into the Swedish company's arachidonic acid franchise.